Gene-editing gets inside job: CRISPR jab eyes first-ever FDA nod
Intellia Therapeutics released data showing its gene-editing therapy lonvoguran ziclumeran (lonvo-z) is still working four years after treatment. The therapy uses CRISPR-Cas9 to disable the gene for prekallikrein in the liver, targeting hereditary angioedema, a disorder causing dangerous swelling. The FDA is expected to decide by 10 March. If approved, it would be the first CRISPR medicine delivered inside the body, unlike Casgevy, which edits cells removed from patients. Last year, the FDA paused two other Intellia studies after a participant died of liver damage. It lifted the hold this year.
Why it matters: If approved, lonvo-z would be the first CRISPR medicine that edits genes inside the body, offering people with hereditary angioedema a possible lasting treatment, though safety concerns from a prior liver-related death remain.
Comments
No comments yet.